Weijia Fang

Zhejiang Chinese Medical University — China

Medicine · Health Sciences

42h-index7.9kcitations257works11.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(65), Colorectal Cancer Treatments and Studies(56), Pancreatic and Hepatic Oncology Research(34), Cancer Genomics and Diagnostics(34), Hepatocellular Carcinoma Treatment and Prognosis(29)

Publications256 total

Sensitized mast cells for targeted drug delivery and augmented cancer immunotherapy
Cell·2025· 3 cited
Sodium valproate drives propionylation-mediated epigenetic reprogramming to enhance mesothelin CAR-T cell therapy in solid tumors
Molecular Therapy·2025Open Access
NKG2D CAR-NK adoptive cellular immunotherapy combined with or without PD-1 blockade in the treatment of patients with metastatic colorectal cancer: an exploratory study
Cancer Immunology Immunotherapy·2025· 5 citedOpen Access
Expression of membrane-bound Interleukin-15 sustains the growth and survival of CAR-NK cells
International Immunopharmacology·2025· 1 cited
The facilitators and barriers of emotional well-being in Chinese adolescents with epilepsy based on the PERMA model: A qualitative study
Epilepsy & Behavior·2025
Dual-stage mechanical response and energy dissipation in double-negative metamaterials
IET conference proceedings.·2025
Injectable HMME‐Loading Emulsion Hydrogel for Ultrasound‐Triggered Release and Enhanced Sonodynamic Immunotherapy
Advanced Healthcare Materials·2025· 1 cited
Preclinical development and a phase 1 trial of IMC001, an EpCAM-targeted CAR-T cell therapy, in patients with advanced gastric cancer
Molecular Therapy·2025· 2 cited
Edge Intelligence with Spiking Neural Networks
arXiv (Cornell University)·2025Open Access
Biweekly CAPOX versus triweekly CAPOX in the adjuvant therapy of post-surgery CRC: A randomized controlled trial
PLoS ONE·2025Open Access
Spatially resolved C1QC+ macrophage-CD4+ T cell niche in colorectal cancer microenvironment: implications for immunotherapy response
Cell Discovery·2025· 6 citedOpen Access
Amplifying Anti‐Tumor Immune Responses via Mitochondria‐Targeting Near‐Infrared Photodynamic Therapy
Advanced Science·2025· 4 citedOpen Access
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial
The Lancet·2025· 58 citedOpen Access
Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of physician's choice (TPC) for previously treated advanced gastric or gastroesophageal junction cancer (G/GEJC): Primary results from a randomized, open-label, phase II trial (CT041-ST-01).
Journal of Clinical Oncology·2025· 2 cited
RETRACTED: Phase 1 clinical trial of EpCAM CAR-T cell therapy in patients with gastrointestinal cancers.
Journal of Clinical Oncology·2025
Assessing the safety and efficacy of GT201: A first-in-class autologous tumor-infiltrating lymphocyte monotherapy in advanced solid tumors.
Journal of Clinical Oncology·2025· 1 cited
Intraperitoneal infusion of NKG2D CAR-NK cells induces endogenous CD8+ T cell activation in patients with advanced colorectal cancer
Molecular Therapy·2025· 9 citedOpen Access
DEMAC-Net: A Dual-Encoder Multiattention Collaborative Network for Cervical Nerve Pathway and Adjacent Anatomical Structure Segmentation
Ultrasound in Medicine & Biology·2025· 2 cited
Neoadjuvant Sintilimab Combined with Gemcitabine and Cisplatin (GP) for Muscle-Invasive Bladder Cancer (MIBC) Patients Followed by Selective Bladder Sparing Surgery: A Phase 2 Trial
Cancer Research and Treatment·2025Open Access
Clca1 deficiency exacerbates colitis susceptibility via impairment of mucus barrier integrity and gut microbiota homeostasis
Microbiological Research·2025
page 1 of 13Next →

Frequent Co-authors

Peng Zhao(16), Xuanwen Bao(12), Zhenggang Ren(11), Yuxian Bai(10), Lulu Liu(10), Zhou Tong(10), Yi Zheng(9), Hangyu Zhang(9), Xiaomeng Dai(9), Shukui Qin(8), Xiaoyan Lin(7), Xiaohong Chen(7), Qihan Fu(7), Zhiqiang Meng(6), Weiqin Jiang(6), Zhendong Chen(5), Rui‐Hua Xu(5), Xudong Zhu(5), Yuzhi Jin(5), Jianping Xiong(4)